Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ZSAN
- CUSIP: N/A
- Web: www.zosanopharma.com
Capitalization:- Market Cap: $38.02 million
- Outstanding Shares: 39,230,000
Average Prices:- 50 Day Moving Avg: $0.95
- 200 Day Moving Avg: $0.95
- 52 Week Range: $0.45 - $3.54
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.26
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.56 per share
- Price / Book: 1.71
Profitability:- EBIDTA: ($24,930,000.00)
- Return on Equity: -172.90%
- Return on Assets: -89.92%
Debt:- Current Ratio: 3.25%
- Quick Ratio: 3.25%
Misc:- Average Volume: 859,986 shs.
- Beta: 2.68
- Short Ratio: 18.95
Frequently Asked Questions for Zosano Pharma Corporation (NASDAQ:ZSAN)
What is Zosano Pharma Corporation's stock symbol?
Zosano Pharma Corporation trades on the NASDAQ under the ticker symbol "ZSAN."
How were Zosano Pharma Corporation's earnings last quarter?
Zosano Pharma Corporation (NASDAQ:ZSAN) announced its earnings results on Thursday, August, 10th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. During the same quarter in the prior year, the company posted ($0.54) earnings per share. View Zosano Pharma Corporation's Earnings History.
When will Zosano Pharma Corporation make its next earnings announcement?
Where is Zosano Pharma Corporation's stock going? Where will Zosano Pharma Corporation's stock price be in 2017?
2 equities research analysts have issued 12-month price targets for Zosano Pharma Corporation's shares. Their predictions range from $3.00 to $4.00. On average, they expect Zosano Pharma Corporation's share price to reach $3.50 in the next twelve months. View Analyst Ratings for Zosano Pharma Corporation.
Who are some of Zosano Pharma Corporation's key competitors?
Some companies that are related to Zosano Pharma Corporation include Pfenex (PFNX), Rexahn Pharmaceuticals (RNN), Ergomed PLC (ERGO), ImmuPharma PLC (IMM), Applied Genetic Technologies Corporation (AGTC), Akari Therapeutics PLC (AKTX), Flex Pharma (FLKS), Motif Bio PLC (MTFB), TRACON Pharmaceuticals (TCON), Microbot Medical (MBOT), Endocyte (ECYT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), OptiBiotix Health PLC (OPTI), Xenon Pharmaceuticals (XENE), Leap Therapeutics (LPTX), Proteostasis Therapeutics (PTI) and Avacta Group Plc (AVCT).
Who are Zosano Pharma Corporation's key executives?
Zosano Pharma Corporation's management team includes the folowing people:
- John P. Walker, Chairman of the Board, President, Chief Executive Officer
- Georgia L. Erbez, Interim Chief Financial Officer, Chief Business Officer
- Eric Scharin, Vice President - Technical Operations
- Thorsten von Stein M.D. Ph.D., Chief Medical Officer
- Joseph P. Hagan, Director
- Bruce D. Steel, Director
- Troy E. Wilson Ph.D. J.D., Independent Director
- Kleanthis G. Xanthopoulos Ph.D., Independent Director
When did Zosano Pharma Corporation IPO?
(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
Who owns Zosano Pharma Corporation stock?
Zosano Pharma Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (4.53%), Vanguard Group Inc. (3.11%), Nexthera Capital LP (1.07%), Victory Capital Management Inc. (0.60%), Granite Point Capital Management L.P. (0.38%) and Geneva Advisors LLC (0.26%). Company insiders that own Zosano Pharma Corporation stock include Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma Corporation.
Who sold Zosano Pharma Corporation stock? Who is selling Zosano Pharma Corporation stock?
Who bought Zosano Pharma Corporation stock? Who is buying Zosano Pharma Corporation stock?
Zosano Pharma Corporation's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Zosano Pharma Corporation stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker and Konstantinos Alataris. View Insider Buying and Selling for Zosano Pharma Corporation.
How do I buy Zosano Pharma Corporation stock?
Shares of Zosano Pharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zosano Pharma Corporation's stock price today?
One share of Zosano Pharma Corporation stock can currently be purchased for approximately $0.96.
MarketBeat Community Rating for Zosano Pharma Corporation (NASDAQ ZSAN)MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Zosano Pharma Corporation (NASDAQ:ZSAN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $3.50 (266.11% upside) |
Analysts' Ratings History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/24/2017 | Piper Jaffray Companies | Initiated Coverage | Overweight | $4.00 | Low |  |
| 3/11/2017 | Roth Capital | Set Price Target | Buy | $3.00 | Medium | |
| 8/11/2016 | Ladenburg Thalmann Financial Services | Downgrade | Buy -> Neutral | | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Zosano Pharma Corporation (NASDAQ:ZSAN)Earnings History by Quarter for Zosano Pharma Corporation (NASDAQ ZSAN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.15) | | | | | N/A | |
| 8/10/2017 | Q2 2017 | ($0.15) | ($0.17) | | | View | N/A | |
| 5/9/2017 | Q1 2017 | ($0.30) | ($0.34) | | | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.45) | ($0.46) | | | View | N/A | |
| 8/10/2016 | Q2 | ($0.50) | ($0.54) | | | View | N/A | |
| 5/12/2016 | Q1 | ($0.56) | ($0.68) | | | View | Listen | |
| 3/29/2016 | Q4 | ($0.67) | ($0.64) | | | View | Listen | |
| 11/9/2015 | Q315 | ($0.61) | ($0.72) | $380.00 million | | View | N/A | |
| 8/12/2015 | Q215 | ($0.53) | ($0.63) | $0.22 million | $0.10 million | View | N/A | |
| 3/25/2015 | | ($0.64) | ($1.10) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Zosano Pharma Corporation (NASDAQ:ZSAN)2017 EPS Consensus Estimate: ($1.06)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.43) | ($0.43) | ($0.43) |
| Q2 2017 | 1 | ($0.18) | ($0.18) | ($0.18) |
| Q3 2017 | 1 | ($0.21) | ($0.21) | ($0.21) |
| Q4 2017 | 1 | ($0.24) | ($0.24) | ($0.24) |
(Data provided by Zacks Investment Research)
Dividend History for Zosano Pharma Corporation (NASDAQ:ZSAN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Zosano Pharma Corporation (NASDAQ:ZSAN)Insider Ownership Percentage: 2.95%
Institutional Ownership Percentage: 22.66%
Insider Trades by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | Georgia Erbez | CFO | Buy | 68,000 | $1.32 | $89,760.00 | |
| 5/25/2017 | John Peter Walker | CEO | Buy | 73,716 | $1.36 | $100,253.76 | |
| 2/13/2017 | Enterprise Associates 12 New | Major Shareholder | Sell | 1,099,996 | $2.01 | $2,210,991.96 | |
| 9/16/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 7,471 | $0.75 | $5,603.25 | |
| 9/13/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 10,000 | $0.74 | $7,400.00 | |
| 8/29/2016 | M James Barrett | Major Shareholder | Sell | 50,000 | $1.01 | $50,500.00 | |
| 8/24/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 1,200 | $1.21 | $1,452.00 | |
| 8/19/2016 | Donald J Kellerman | VP | Buy | 15,920 | $1.32 | $21,014.40 | |
| 8/19/2016 | Georgia Erbez | CFO | Buy | 47,750 | $1.32 | $63,030.00 | |
| 8/19/2016 | John Peter Walker | Director | Buy | 63,700 | $1.32 | $84,084.00 | |
| 8/19/2016 | Konstantinos Alataris | CEO | Buy | 127,389 | $1.32 | $168,153.48 | |
| 7/21/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 23,681 | $1.27 | $30,074.87 | |
| 7/13/2016 | Enterprise Associates 12 New | Major Shareholder | Sell | 13,382 | $1.20 | $16,058.40 | |
| 1/30/2015 | Enterprise Associates 12 New | Major Shareholder | Buy | 23,457 | $11.00 | $258,027.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Zosano Pharma Corporation (NASDAQ:ZSAN)
Latest Headlines for Zosano Pharma Corporation (NASDAQ:ZSAN)
| Source: |
|
| Date | Headline |
|---|
 | Zosano Presents Data from ZOTRIP Study at International Headache Society
finance.yahoo.com - September 14 at 12:11 PM |
| Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines”
finance.yahoo.com - August 29 at 10:08 AM |
 | Analysts Expect Zosano Pharma Corporation (ZSAN) to Announce -$0.15 EPS
www.americanbankingnews.com - August 25 at 4:10 AM |
 | Zosano Pharma's (ZSAN) CEO John Walker on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 12 at 9:06 AM |
| Zosano Pharma Corporation (ZSAN) vs. Acorda Therapeutics (ACOR) Head to Head Comparison
www.americanbankingnews.com - August 11 at 4:58 PM |
 | Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update
globenewswire.com - August 11 at 9:24 AM |
| Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update
finance.yahoo.com - August 11 at 9:24 AM |
| Zosano Pharma Corporation (ZSAN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 10 at 6:21 PM |
| Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update - GlobeNewswire (press release)
globenewswire.com - August 4 at 10:21 AM |
 | Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update - Nasdaq
www.nasdaq.com - August 2 at 9:02 AM |
| Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update
finance.yahoo.com - August 2 at 9:02 AM |
 | Zosano Pharma (ZSAN) Announces Positive Phase 1 Data of Zolmitriptan Delivery - StreetInsider.com
www.streetinsider.com - August 1 at 8:08 AM |
| Zosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal
finance.yahoo.com - August 1 at 8:08 AM |
| Zosano Pharma Corporation (ZSAN) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
| ROTY Edition 1 Volume 11: Our First Sell - Seeking Alpha
seekingalpha.com - July 13 at 8:40 PM |
| Zosano Pharma (ZSAN) Reports Outcome of End of Phase 2 Meetings with FDA - StreetInsider.com
www.streetinsider.com - June 27 at 9:35 AM |
| Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA
finance.yahoo.com - June 27 at 9:35 AM |
| Comparing Zosano Pharma Corporation (ZSAN) and GW Pharmaceuticals PLC (GWPH)
www.americanbankingnews.com - June 24 at 12:14 PM |
| Analysts Expect Zosano Pharma Corporation (ZSAN) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - June 21 at 12:08 PM |
| Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
www.globenewswire.com - June 14 at 4:32 PM |
| Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - June 14 at 4:32 PM |
| Zosano Pharma (ZSAN) Presents Additional Data from ZOTRIP Study - StreetInsider.com
www.streetinsider.com - June 12 at 3:16 PM |
| Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom
finance.yahoo.com - June 12 at 3:16 PM |
| Zosano Pharma Corp (ZSAN) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - June 6 at 6:16 PM |
| Zosano to Present Migraine Data at Three Industry-Leading Conferences - GlobeNewswire (press release)
globenewswire.com - June 2 at 8:18 AM |
| Zosano to Present Migraine Data at Three Industry-Leading Conferences
finance.yahoo.com - June 2 at 8:18 AM |
| Zosano Pharma Corp (ZSAN) Interim CEO John Peter Walker Bought $100,254 of Shares
finance.yahoo.com - May 27 at 6:58 AM |
| Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 26 at 8:55 AM |
| Zosano Pharma Corp (ZSAN) CFO Purchases $89,760.00 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM |
| Zosano Pharma Corp (ZSAN) CEO Acquires $100,253.76 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM |
| Zosano Pharma Corp (ZSAN) Announces Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 10 at 5:18 PM |
 | Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:45 AM |
| Zosano Pharma (ZSAN) Reports Q4 Loss of $0.34; CEO Resigns
www.streetinsider.com - May 9 at 9:00 PM |
| Investor Network: Zosano Pharma Corp. to Host Earnings Call
finance.yahoo.com - May 9 at 9:00 PM |
| Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes
finance.yahoo.com - May 9 at 9:00 PM |
| Zosano Pharma Corp (ZSAN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:00 AM |
 | Zosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update
feeds.benzinga.com - May 8 at 5:43 AM |
| Zosano Pharma Corp (ZSAN) Earns Media Impact Rating of -0.12
www.americanbankingnews.com - May 4 at 8:20 AM |
| Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - May 3 at 12:04 AM |
| Zosano Pharma Corp (ZSAN) Getting Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 29 at 9:16 AM |
| Short Interest in Zosano Pharma Corp (ZSAN) Grows By 35.1%
www.americanbankingnews.com - April 29 at 1:17 AM |
| Zosano Pharma Corp (ZSAN) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 3:11 PM |
| Zosano Pharma Corp (ZSAN) Receiving Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 20 at 9:17 AM |
| Zosano Pharma Corp (ZSAN) Earns Daily Coverage Optimism Rating of -0.10
www.americanbankingnews.com - April 16 at 8:48 AM |
| Zosano Pharma Corp (ZSAN) Earning Somewhat Negative News Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 9:21 AM |
| Zosano Pharma Corp (ZSAN) Short Interest Down 12.5% in March
www.americanbankingnews.com - April 12 at 7:17 AM |
| Analysts Anticipate Zosano Pharma Corp (ZSAN) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 11 at 6:07 PM |
| Shkreli Gives Zosano a Giant Headache
finance.yahoo.com - April 7 at 1:41 PM |
| Zosano Pharma Corp (ZSAN) Receives New Coverage from Analysts at Piper Jaffray Companies
www.americanbankingnews.com - March 30 at 8:23 AM |
| Zosano Pharma Corp (ZSAN) Short Interest Update
www.americanbankingnews.com - March 28 at 7:07 AM |
Zosano Pharma Corporation (ZSAN) Chart for Friday, September, 22, 2017
